blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2941439

EP2941439 - HUMAN SERUM ALBUMIN BINDING COMPOUNDS AND FUSION PROTEINS THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  07.12.2018
Database last updated on 07.10.2024
FormerThe patent has been granted
Status updated on  29.12.2017
FormerGrant of patent is intended
Status updated on  24.08.2017
FormerExamination is in progress
Status updated on  04.11.2016
Most recent event   Tooltip03.07.2020Lapse of the patent in a contracting state
New state(s): CY, HU, MK		published on 05.08.2020  [2020/32]
Applicant(s)For all designated states
Covagen AG
Gubelstrasse 34
6300 Zug / CH
[2016/07]
Former [2015/46]For all designated states
Covagen AG
Wagistrasse 25
8952 Zürich-Schlieren / CH
Inventor(s)01 / BULLER, Fabian
Gubelstrasse34
CH-6300 Zug / CH
02 / WÜLLNER, Ulrich
Gubelstrasse 34
CH-6300 Zug / CH
03 / ZBINDEN, Irene
"-"
deceased / CH
04 / ATTINGER-TOLLER, Isabella
Gubelstrasse 34
CH-6300 Zug / CH
05 / VON DER BEY, Ulrike
Gubelstrasse 34
CH-6300 Zug / CH
06 / KÖNIG-FRIEDRICH, Susann
Gubelstrasse 34
CH-6300 Zug / CH
07 / BERTSCHINGER, Julian
Gubelstrasse 34
CH-6300 Zug / CH
08 / GRABULOVSKI, Dragan
Gubelstrasse 34
CH-6300 Zug / CH
09 / HENNE, Patricia
Gubelstrasse 34
CH-6300 Zug / CH
 [2018/04]
Former [2015/46]01 / BULLER, Fabian
Hohenklingenallee 3
8049 Zürich / CH
02 / WÜLLNER, Ulrich
Dorfstrasse 49b
8102 Oberengstringen / CH
03 / ZBINDEN, Irene
Landenbergweg 18
8488 Turbenthal / CH
04 / ATTINGER-TOLLER, Isabella
Stettbachstrasse 50
8051 Zürich / CH
05 / VON DER BEY, Ulrike
Neue Halde 3/1
78359 Orsingen-Nenzingen / DE
06 / KÖNIG-FRIEDRICH, Susann
Hauptstrasse 28
78244 Gottmadingen / DE
07 / BERTSCHINGER, Julian
Am Tobelbach 17
8913 Ottenbach / CH
08 / GRABULOVSKI, Dragan
Riedhofstrasse 57
8049 Zürich / CH
09 / HENNE, Patricia
Kirchenstrasse 35
8957 Spreitenbach / CH
Representative(s)Verhage, Richard Abraham, et al
Janssen Vaccines & Prevention B.V.
Archimedesweg 4-6
2333 CN Leiden / NL
[N/P]
Former [2018/05]Verhage, Richard Abraham, et al
Janssen Vaccines & Prevention B.V.
IP Department
Archimedesweg 4-6
2333 CN Leiden / NL
Former [2015/46]Verhage, Richard Abraham, et al
Crucell Holland B.V.
IP Department
Archimedesweg 4-6
2333 CN Leiden / NL
Application number, filing date13821463.018.12.2013
[2015/46]
WO2013EP77227
Priority number, dateEP2013015017103.01.2013         Original published format: EP 13150171
[2015/46]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014106583
Date:10.07.2014
Language:EN
[2014/28]
Type: A1 Application with search report 
No.:EP2941439
Date:11.11.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 10.07.2014 takes the place of the publication of the European patent application.
[2015/46]
Type: B1 Patent specification 
No.:EP2941439
Date:31.01.2018
Language:EN
[2018/05]
Search report(s)International search report - published on:EP10.07.2014
ClassificationIPC:C07K14/765, C07K14/47, C12N1/21, C12N1/15, C12N5/10, C07K16/18
[2017/35]
CPC:
C12N9/12 (EP,US); A61P35/00 (EP); A61P37/02 (EP);
A61P5/00 (EP); A61P7/00 (EP); A61P7/02 (EP);
C07K14/47 (EP,US); C07K14/765 (EP,US); C07K16/18 (US);
C07K2317/31 (US); C07K2319/31 (EP,US); C12Y207/10002 (EP,US) (-)
Former IPC [2015/46]C07K14/765, C07K14/47, C12N1/21, C12N1/15, C12N5/10
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/46]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:HUMANE SERUMALBUMIN BINDENDE VERBINDUNGEN UND FUSIONSPROTEINE DARAUS[2017/35]
English:HUMAN SERUM ALBUMIN BINDING COMPOUNDS AND FUSION PROTEINS THEREOF[2015/46]
French:COMPOSÉS DE LIAISON D'ALBUMINE DE SÉRUM HUMAIN ET LEURS PROTÉINES DE FUSION[2017/35]
Former [2015/46]HUMANSERUMALBUMINBINDENDE VERBINDUNGEN UND FUSIONSPROTEINE DARAUS
Former [2015/46]COMPOSÉS LIANT L'ALBUMINE SÉRIQUE HUMAINE ET PROTÉINES DE FUSION CORRESPONDANTES
Entry into regional phase02.07.2015National basic fee paid 
02.07.2015Designation fee(s) paid 
02.07.2015Examination fee paid 
Examination procedure02.07.2015Examination requested  [2015/46]
08.02.2016Amendment by applicant (claims and/or description)
22.07.2016Despatch of a communication from the examining division (Time limit: M04)
03.11.2016Reply to a communication from the examining division
23.12.2016Despatch of a communication from the examining division (Time limit: M06)
26.06.2017Reply to a communication from the examining division
25.08.2017Communication of intention to grant the patent
18.12.2017Fee for grant paid
18.12.2017Fee for publishing/printing paid
18.12.2017Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  22.07.2016
Opposition(s)02.11.2018No opposition filed within time limit [2019/02]
Fees paidRenewal fee
10.12.2015Renewal fee patent year 03
13.12.2016Renewal fee patent year 04
12.12.2017Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU18.12.2013
AL31.01.2018
AT31.01.2018
CY31.01.2018
CZ31.01.2018
DK31.01.2018
EE31.01.2018
ES31.01.2018
FI31.01.2018
HR31.01.2018
IT31.01.2018
LT31.01.2018
LV31.01.2018
MC31.01.2018
MK31.01.2018
NL31.01.2018
PL31.01.2018
PT31.01.2018
RO31.01.2018
RS31.01.2018
SE31.01.2018
SI31.01.2018
SK31.01.2018
SM31.01.2018
TR31.01.2018
BG30.04.2018
NO30.04.2018
GR01.05.2018
IS31.05.2018
[2020/31]
Former [2020/28]AL31.01.2018
AT31.01.2018
CZ31.01.2018
DK31.01.2018
EE31.01.2018
ES31.01.2018
FI31.01.2018
HR31.01.2018
IT31.01.2018
LT31.01.2018
LV31.01.2018
MC31.01.2018
NL31.01.2018
PL31.01.2018
PT31.01.2018
RO31.01.2018
RS31.01.2018
SE31.01.2018
SI31.01.2018
SK31.01.2018
SM31.01.2018
TR31.01.2018
BG30.04.2018
NO30.04.2018
GR01.05.2018
IS31.05.2018
Former [2020/16]AL31.01.2018
AT31.01.2018
CZ31.01.2018
DK31.01.2018
EE31.01.2018
ES31.01.2018
FI31.01.2018
HR31.01.2018
IT31.01.2018
LT31.01.2018
LV31.01.2018
MC31.01.2018
NL31.01.2018
PL31.01.2018
RO31.01.2018
RS31.01.2018
SE31.01.2018
SI31.01.2018
SK31.01.2018
SM31.01.2018
TR31.01.2018
BG30.04.2018
NO30.04.2018
GR01.05.2018
IS31.05.2018
Former [2019/40]AL31.01.2018
AT31.01.2018
CZ31.01.2018
DK31.01.2018
EE31.01.2018
ES31.01.2018
FI31.01.2018
HR31.01.2018
IT31.01.2018
LT31.01.2018
LV31.01.2018
MC31.01.2018
NL31.01.2018
PL31.01.2018
RO31.01.2018
RS31.01.2018
SE31.01.2018
SI31.01.2018
SK31.01.2018
SM31.01.2018
BG30.04.2018
NO30.04.2018
GR01.05.2018
IS31.05.2018
Former [2019/13]AL31.01.2018
AT31.01.2018
CZ31.01.2018
DK31.01.2018
EE31.01.2018
ES31.01.2018
FI31.01.2018
HR31.01.2018
IT31.01.2018
LT31.01.2018
LV31.01.2018
NL31.01.2018
PL31.01.2018
RO31.01.2018
RS31.01.2018
SE31.01.2018
SI31.01.2018
SK31.01.2018
SM31.01.2018
BG30.04.2018
NO30.04.2018
GR01.05.2018
IS31.05.2018
Former [2018/52]AL31.01.2018
AT31.01.2018
CZ31.01.2018
DK31.01.2018
EE31.01.2018
ES31.01.2018
FI31.01.2018
HR31.01.2018
IT31.01.2018
LT31.01.2018
LV31.01.2018
NL31.01.2018
PL31.01.2018
RO31.01.2018
RS31.01.2018
SE31.01.2018
SK31.01.2018
SM31.01.2018
BG30.04.2018
NO30.04.2018
GR01.05.2018
IS31.05.2018
Former [2018/51]AL31.01.2018
AT31.01.2018
CZ31.01.2018
DK31.01.2018
EE31.01.2018
ES31.01.2018
FI31.01.2018
HR31.01.2018
IT31.01.2018
LT31.01.2018
LV31.01.2018
NL31.01.2018
PL31.01.2018
RO31.01.2018
RS31.01.2018
SE31.01.2018
SK31.01.2018
BG30.04.2018
NO30.04.2018
GR01.05.2018
IS31.05.2018
Former [2018/50]AL31.01.2018
AT31.01.2018
CZ31.01.2018
EE31.01.2018
ES31.01.2018
FI31.01.2018
HR31.01.2018
IT31.01.2018
LT31.01.2018
LV31.01.2018
NL31.01.2018
PL31.01.2018
RO31.01.2018
RS31.01.2018
SE31.01.2018
SK31.01.2018
BG30.04.2018
NO30.04.2018
GR01.05.2018
IS31.05.2018
Former [2018/47]AL31.01.2018
AT31.01.2018
ES31.01.2018
FI31.01.2018
HR31.01.2018
IT31.01.2018
LT31.01.2018
LV31.01.2018
NL31.01.2018
PL31.01.2018
RS31.01.2018
SE31.01.2018
BG30.04.2018
NO30.04.2018
GR01.05.2018
IS31.05.2018
Former [2018/46]AL31.01.2018
AT31.01.2018
ES31.01.2018
FI31.01.2018
HR31.01.2018
LT31.01.2018
LV31.01.2018
NL31.01.2018
PL31.01.2018
RS31.01.2018
SE31.01.2018
BG30.04.2018
NO30.04.2018
GR01.05.2018
IS31.05.2018
Former [2018/40]AT31.01.2018
ES31.01.2018
FI31.01.2018
HR31.01.2018
LT31.01.2018
LV31.01.2018
NL31.01.2018
PL31.01.2018
RS31.01.2018
SE31.01.2018
BG30.04.2018
NO30.04.2018
GR01.05.2018
IS31.05.2018
Former [2018/39]AT31.01.2018
ES31.01.2018
FI31.01.2018
HR31.01.2018
LT31.01.2018
LV31.01.2018
NL31.01.2018
PL31.01.2018
RS31.01.2018
SE31.01.2018
NO30.04.2018
GR01.05.2018
IS31.05.2018
Former [2018/37]ES31.01.2018
FI31.01.2018
HR31.01.2018
LT31.01.2018
NL31.01.2018
PL31.01.2018
NO30.04.2018
GR01.05.2018
Former [2018/36]ES31.01.2018
FI31.01.2018
HR31.01.2018
LT31.01.2018
NL31.01.2018
PL31.01.2018
NO30.04.2018
Former [2018/35]FI31.01.2018
HR31.01.2018
LT31.01.2018
NL31.01.2018
NO30.04.2018
Cited inInternational search[ID]EP1892248  (EIDGENOESS TECH HOCHSCHULE [CH]) [ID] 1-15 * Whole document, especially example 2 and figure 5 *;
 [A]EP2524927  (COVAGEN AG [CH]) [A] 1-15 * Whole document, especially claim 1 *;
 [A]  - LEE C-H ET AL, "A single amino acid in the SH3 domain of Hck determines its high affinity and specificity in binding to HIV-1 Nef protein", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, (19950101), vol. 14, no. 20, ISSN 0261-4189, pages 5006 - 5015, XP002236097 [A] 1-15 * abstract *
 [AD]  - ERPEL T ET AL, "Mutational analysis of the Src SH3 domain: the same residues of the ligand binding surface are important for intra- and intermolecular interactions.", THE EMBO JOURNAL 1 MAR 1995, (19950301), vol. 14, no. 5, ISSN 0261-4189, pages 963 - 975, XP002696729 [AD] 1-15 * the whole document *
by applicantWO9101743
 WO0145746
 WO02076489
 WO2004041865
 EP2054432
 US6080560
 US4946778
 EP0239400
 WO9007861
    - DENNIS MS ET AL., J BIOL CHEM, (2002), vol. 277, no. 38, pages 35035 - 35043
    - JONSSON A. ET AL., PROTEIN ENG DES SEL, (2008), vol. 21, no. 8, pages 515 - 527
    - HOLT L. J. ET AL., PROTEIN ENG DES SEL, (2008), vol. 21, pages 283 - 288
    - WALKER, A. ET AL., PROTEIN ENG DES SE, (2010), vol. 123, pages 271 - 278
    - SKERRA A., J. MOL. RECOGNIT., (2000), vol. 13, pages 167 - 187
    - GEBAUER M; SKERRA A., CURR OPINION IN CHEMICAL BIOLOGY, (2009), vol. 13, pages 245 - 255
    - BERTSCHINGER J. ET AL., PROTEIN ENG DES SEL, (2007), vol. 20, no. 2, pages 57 - 68
    - WEBB MILLER; DAVID J. LIPMAN, "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", NUCLEIC ACIDS RES., (1997), vol. 25, pages 3389 - 3402
    - SANGASTINO ET AL., BLOOD, (2012), vol. 120, no. 12, pages 2405 - 2411
    - MUSACCHIO ET AL., PROG. BIOPHYS. MOL. BIOL., (1994), vol. 61, pages 283 - 297
    - MUSACCHIO A., ADVANCES IN PROTEIN CHEMISTRY, (2003), vol. 61, pages 211 - 268
    - REN ET AL., SCIENCE, (1993), vol. 259, pages 1157 - 1161
    - KARKKAINEN ET AL., EMBO REP., (2006), vol. 7, pages 186 - 191
    - KOYAMA ET AL., CELL, (1993), vol. 72, no. 6, pages 945 - 952
    - LARSON ET AL., PROTEIN SCIENCE, (2000), vol. 9, pages 2170 - 2180
    - ERPEL ET AL., "Mutational analysis of the Src SH3 domain: the same residues of the ligand binding surface are important for intra- and intermolecular interactions", EMBO J., (1995), vol. 14, no. 5, pages 963 - 75
    - GRABULOVSKI ET AL., JBC, (2007), vol. 282, pages 3196 - 3204
    - HOLT ET AL., PROTEIN ENGINEERING, DESIGN & SELECTION, (2008), vol. 21, no. 5, pages 283 - 288
    - DENNIS ET AL., J BIOL CHEM, (2002), vol. 277, no. 38, pages 35035 - 35043
    - ALBERTS ET AL., Molecular Biology of the Cell, GARLAND SCIENCE, pages 518 - 519
    - STROHL W., CURR OPIN BIOTECHNOL, (2009), vol. 20, pages 685 - 691
    - BAEUERLE PA ET AL., CURR OPIN MOL THER., (2003), vol. 5, no. 4, pages 413 - 419
    - WOLF E. ET AL., DRUG DISCOV TODAY, (2005), vol. 10, no. 18, pages 1237 - 1244
    - BAUERLE PA; REINHARDT C., CANCER RES, (2009), vol. 69, no. 12, pages 4941 - 4944
    - FRIEDRICH M. ET AL., MOL CANCER THER., (2012), vol. 11, pages 2664 - 2673
    - BRAASCH; COREY, CHEMISTRY & BIOLOGY, (2001), vol. 8, pages 1 - 7
    - OWENS, PROC. NATL. ACAD. SCI. USA, (2001), vol. 98, pages 1471 - 1476
    - GHAHROUDI ET AL., FEBS LETTERS, (1997), vol. 414, pages 521 - 526
    - SCHLATTER ET AL., MABS, (2012), vol. 4, no. 4, pages 497 - 50
    - GRABULOVSKI D. ET AL., J BIOL CHEM, (2007), vol. 282, pages 3196 - 3204
    - VITI, F. ET AL., METHODS ENZYMOL., (2000), vol. 326, pages 480 - 505
    - BERTSCHINGER ET AL., PROTEIN ENG DES SEL, (2007), vol. 20, no. 2, pages 57 - 68
    - DREIER, INT. J. CANCER, (2002), vol. 100, pages 690 - 697
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.